New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
05:55 EDTMMM, MMM, GWW, GWW, UNP, UNP, SWK, SWK, LUV, LUV, RTN, RTN, PCP, PCP, MKC, MKC, LMT, LMT, KEY, KEY, EQT, EQT, DOV, DOV, CELG, CELG, BMY, BMY, BAX, BAX, ABC, ABC, ARG, ARG, XRX, XRXCompanies reporting Before the Market Open on Thursday, January 24
Notable companies reporting before the opening bell on Thursday include 3M Co (MMM), Airgas (ARG), AmerisourceBergen (ABC), Baxter International (BAX), Bristol-Myers Squibb (BMY), Celgene (CELG), Dover (DOV), EQT (EQT), KeyCorp (KEY), Lockheed Martin (LMT), McCormick & Company (MKC), Precision Castparts (PCP), Raytheon (RTN), Southwest Airlines (LUV), Stanley Black & Decker (SWK), Union Pacific (UNP), W.W. Grainger (GWW), and Xerox (XRX).
News For MMM;ARG;ABC;BAX;BMY;CELG;DOV;EQT;KEY;LMT;MKC;PCP;RTN;LUV;SWK;UNP;GWW;XRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
October 10, 2014
15:42 EDTLUVPlane held on Las Vegas tarmac over Ebola scare, Reuters reports
Subscribe for More Information
10:03 EDTBMYBristol-Myers receives orphan status for melanoma treatment
Subscribe for More Information
09:54 EDTBAXJPMorgan medical supplies analyst holds an analyst/industry conference call
Subscribe for More Information
08:41 EDTCELGCelgene reports apremilast significantly improved preexisting psoriasis in study
Subscribe for More Information
08:39 EDTCELGCelgene says data show Apremilast treatment resulted in improved quality of life
Subscribe for More Information
08:19 EDTBMYMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
October 9, 2014
13:56 EDTRTN, LMTObama calls on Congress to lift defense spending cuts, Politico says
Subscribe for More Information
10:00 EDTSWKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:44 EDTSWKStanley Black & Decker initiated with a Buy at Wunderlich
Target $108.
October 8, 2014
10:06 EDTUNPStephens transportation analysts hold an analyst/industry conference call
Subscribe for More Information
10:00 EDTEQTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:46 EDTLUVSouthwest reports September RPMs up 5.1% to 8.3B
Southwest announced that the company flew 8.3 billion revenue passenger miles in September 2014, a 5.1% increase from the 7.9B RPMs flown in September 2013. Available seat miles increased 0.7% to 10.3B from the September 2013 level of 10.2B. The September 2014 load factor was 80.5%, compared to 77.1% in September 2013. For September, passenger revenue per ASM is estimated to have increased approximately 5% as compared to September 2013. For the third quarter of 2014, the Company flew 28.5B RPMs, compared to 27B RPMs flown for the same period in 2013, an increase of 5.6%. Third quarter 2014 ASMs increased 1.1% to 33.8B from third quarter 2013 ASMs of 33.4B . The third quarter 2014 load factor was 84.4%, compared to 80.8% for the same period in 2013.
08:07 EDTLMTExelis awarded follow-on contract for Lockheed Martin's JASSM
Subscribe for More Information
08:06 EDTKEYAstoria Financial appoints Hugh J. Donlon as Chief Lending Officer
Subscribe for More Information
08:03 EDTBMYBristol-Myers resolves outstanding U.S. litigation on efavirenz
Bristol-Myers Squibb Company says it has "successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva -- efavirenz -- and Atripla products. Accordingly, we believe that loss of exclusivity in the U.S. for efavirenz should not occur until December 2017. Bristol-Myers Squibb remains committed to delivering our medicines and to developing new and innovative treatments to help patients prevail over serious disease. Atripla is currently the #1 prescribed U.S. regimen in its category, with over 8 million prescriptions written since its launch in 2006. Earlier this year the company submitted a new drug application to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate and cobicistat, an investigational pharmacokinetic enhancer. In addition, studies are ongoing for new treatments including an HIV-1 attachment inhibitor, an HIV-1 maturation inhibitor and an anti-PD-L1. The establishment of intellectual property rights allows Bristol-Myers Squibb to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We will continue to defend our intellectual property rights against infringement as we remain focused on providing a deep and broad portfolio of innovative medicines to patients around the world."
08:02 EDTRTNRaytheon realize savings of $300M for U.S. Army on Warfighter training program
Subscribe for More Information
07:19 EDTRTNRaytheon contemplates agreement with Qatar before 2014 end, Reuters says
Subscribe for More Information
07:18 EDTBMYInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
07:11 EDTCELGEuropean Academy of Dermatology and Venereology to hold a conference
23rd EADV Congress is being held in Amsterdam, The Netherlands on October 8-12.
06:57 EDTEQTEQT Corporation initiated with an Accumulate at Global Hunter
Target $107.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use